Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid
    6.
    发明授权
    Purification 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid 有权
    从4-氮杂 - 雄甾烷-17-酸酸中纯化4-氮杂 - 雄甾-1-烯-17-酸

    公开(公告)号:US08664395B2

    公开(公告)日:2014-03-04

    申请号:US13257865

    申请日:2009-04-02

    IPC分类号: C07D221/18 A61K31/435

    CPC分类号: C07J73/005

    摘要: The present invention relates to a process of separation of 4-aza-androst-1-ene-17-oic acid from 4-aza-androstan-17-oic acid, which brings to 4-aza-androst-1-ene-17-oic containing less than 0.05% w/w of 4-aza-androstan-17-oic acid, with high yield and productivity. In particular, the present invention relates to a process for the separation of 4-aza-androstan-17-oic acid from 4-aza-androst-1-ene-17-oic acid, comprising the steps of treating the crude 4-aza-androst-1-ene-17-oic acid with formic acid and recovering the purified 4-aza-androst-1-ene-17-oic acid containing 4-aza-androstan-17-oic acid in w/w % less than 0.05%.

    摘要翻译: 本发明涉及从4-氮杂 - 雄甾烷-17-酸分离4-氮杂 - 雄甾-1-烯-17-酸的方法,其使4-氮杂 - 雄甾-1-烯-17-酸 含有小于0.05%w / w的4-氮杂 - 雄甾烷-17-酸的2-羟基苯甲酸,产率高,生产率高。 特别地,本发明涉及从4-氮杂 - 雄甾-1-烯-17-酸酸分离4-氮杂 - 雄甾烷-17-酸的方法,包括以下步骤:将粗制4-氮杂 - 雄甾-1-烯-17-酸与甲酸反应,并回收纯化的含有4-氮杂 - 雄甾烷-17-酸的4-氮杂 - 雄甾-1-烯-17-酸,w / w% 0.05%。

    Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
    9.
    发明授权
    Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders 失效
    使用非那雄胺,度他雄胺和相关化合物预防或治疗神经系统相关疾病

    公开(公告)号:US07998970B2

    公开(公告)日:2011-08-16

    申请号:US11720650

    申请日:2005-12-02

    摘要: The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy. The demonstrated inhibition of the MPTP appears to constitute a novel principle applicable to all pathological conditions which have underlying excitotoxic/mitochondrial mechanisms, like: amyotrophic lateral sclerosis, Alzheimer's disease, depression, epilepsy, multiple sclerosis, pain, Parkinson's disease, schizophrenia, traumatic brain and spinal chord injury, stroke and other ischemic conditions in the brain.

    摘要翻译: 本发明涉及4-氮杂甾族化合物,特别是非那雄胺/度他雄胺/度他雄胺和度他雄胺,特别优选非那雄胺/度他雄胺/度他雄胺及其药学上可接受的衍生物以及包含所述化合物的组合的新药用途。 本发明还通常特征在于通过振动筛型电压门控钾通道的β亚基和/或通过溶质载体家族25,特别是Aralar(成员12)和腺嘌呤核苷酸转运体1的成员通过神经保护条件的调节剂化合物的使用 &2(成员4&5)和/或通过4-硝基苯基磷酸酶结构域和非神经元SNAP25样蛋白同系物1(NIPSNAP 1)作为神经保护药物,特别是作为预防和/或治疗神经疾病的药物 如痴呆症,帕金森病,阿尔茨海默病,精神分裂症或癫痫。 所显示的MPTP的抑制似乎构成适用于具有潜在兴奋性毒素/线粒体机制的所有病理状况的新颖原理,例如:肌萎缩性侧索硬化,阿尔茨海默病,抑郁症,癫痫,多发性硬化,疼痛,帕金森病,精神分裂症,创伤性脑 和脊髓损伤,脑卒中等缺血状况。